SMAD5 and prostate carcinoma: However, based on immunoblotting analyses in PC3 nuclear lysates and human prostate cancer cells, we propose that RUNX2 localized in the nucleus of cancer tissue is mostly phosphorylated (Figure7F, lane 2); c) Diffuse distribution of Smad-5 was observed in normal and prostate carcinoma sections.